<DOC>
	<DOCNO>NCT00119730</DOCNO>
	<brief_summary>- The purpose study find whether combine short course chemotherapy ( Fludarabine , Mitoxantrone Rituximab ) follow Zevalin effective treating relapse mantle cell lymphoma . - The secondary purpose study determine safety evaluate whether additional benefit Zevalin therapy follow chemotherapy .</brief_summary>
	<brief_title>Chemotherapy Followed Zevalin Relapsed Mantle Cell Lymphoma</brief_title>
	<detailed_description>- Patients receive fludarabine ( day 1-3 ) , mitoxantrone ( day 1 ) , rituximab ( day 1 ) 28-day cycle . - Patients undergo CT scan bone marrow biopsy two cycle . Unless cancer progress , patient receive Zevalin study treatment . - Blood count take every week 12 week . After 12 week , CT scan bone marrow biopsy perform . - Long-term followup 4 year . Physical exam blood work perform every 3 month first two year . Following , physical exam blood work every 6 month another two year . CT scan bone marrow biopsy every 6 month 4 year followup period .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Histologically confirm mantle cell lymphoma 1st 2nd relapse , persistent disease follow induction therapy . Measurable disease ( lymph node &gt; 1.5 cm ) No anticancer therapy three week ( six week Rituximab , nitrosourea Mitomycin C ) prior study initiation , fully recover toxicity associate prior surgery , radiation treatment , chemotherapy , immunotherapy An IRBapproved sign informed consent Age &gt; /= 18 year Expected survival &gt; /= 3 month ECOG performance status 0 , 1 , 2 Acceptable hematologic status within two week prior registration , include : * Absolute neutrophil count ( [ segment neutrophil + band ] x total WBC ) ≥ 1,500/mm3 ; * Platelet count ≥ 100,000/mm3 Female patient pregnant lactate Men woman reproductive potential following accept birth control method ( determine treat physician , however abstinence acceptable method ) Patients previously Phase II drug longterm toxicity expect , patient drug eight week significant post treatment toxicity observe Inclusion Criteria Proceeding Zevalin : Hematologic recovery FMR ( ANC &gt; 1500 , platelets &gt; 100,000 ) Stable respond disease restaging follow two cycle FMR &lt; 25 % bone marrow cellularity involve lymphoma restaging bone marrow biopsy Bone marrow cellularity least 20 % ( include lymphoma normal cell ) Total bilirubin &lt; 2.0 mg/dL ( total bilirubin &gt; 75 % indirect , may use direct bilirubin &lt; 0.8 mg/dL ) Serum creatinine &lt; 2.0 mg/dL No GCSF GMCSF therapy within two week prior Zevalin treatment , neulasta within four week prior Zevalin treatment No evidence alter biodistribution 111InZevalin indicate : 1 . Absent cardiac blood pool day 1 , high liver / spleen uptake 2 . Lung uptake great blood pool day 1 great liver day 23 3 . Kidney ( posterior view ) bowel uptake great liver day 23 Patients impaired bone marrow reserve , indicate one following : * Prior myeloablative therapy allogeneic autologous bone marrow transplantation ( ABMT ) peripheral blood stem cell ( PBSC ) rescue ; * Platelet count &lt; 100,000 cells/mm3 ; * Prior external beam radiation &gt; 25 % active bone marrow ; * History fail stem cell collection Prior radioimmunotherapy Known cardiac ejection fraction &lt; 40 % . In patient prior adriamycin exposure &gt; = 300 mg/m2 , echocardiogram must obtain within three month prior registration Known CNS lymphoma ( lumbar puncture require symptomatic ) Chronic lymphocytic leukemia ( CLL ) HIV AIDSrelated lymphoma Pleural effusion ascites Abnormal liver function : total bilirubin &gt; 2.0 mg/dL ( total bilirubin &gt; 75 % indirect , may use direct bilirubin &gt; 0.8 mg/dL ) Abnormal renal function : serum creatinine &gt; 2.0 mg/dL GCSF GMCSF therapy within two week prior treatment , neulasta within four week Positive direct antiglobulin test Major surgery , diagnostic surgery , within four week Serious nonmalignant disease infection opinion investigator would compromise protocol objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Fludarabine</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Relapsed Mantle Cell Lymphoma</keyword>
</DOC>